- Home
- ACET vs HYPR Comparison
ACET vs HYPR Comparison
Compare ACET & HYPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- HYPR
- Stock Information
- Founded
- ACET 1947
- HYPR 2014
- Country
- ACET United States
- HYPR United States
- Employees
- ACET N/A
- HYPR N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- HYPR Medical Specialities
- Sector
- ACET Health Care
- HYPR Health Care
- Exchange
- ACET Nasdaq
- HYPR Nasdaq
- Market Cap
- ACET 55.1M
- HYPR 54.6M
- IPO Year
- ACET N/A
- HYPR N/A
- Fundamental
- Price
- ACET $0.75
- HYPR $0.85
- Analyst Decision
- ACET Buy
- HYPR Strong Buy
- Analyst Count
- ACET 6
- HYPR 3
- Target Price
- ACET $6.00
- HYPR $1.06
- AVG Volume (30 Days)
- ACET 768.4K
- HYPR 5.7M
- Earning Date
- ACET 05-06-2025
- HYPR 05-13-2025
- Dividend Yield
- ACET N/A
- HYPR N/A
- EPS Growth
- ACET N/A
- HYPR N/A
- EPS
- ACET N/A
- HYPR N/A
- Revenue
- ACET N/A
- HYPR $11,732,000.00
- Revenue This Year
- ACET N/A
- HYPR $13.22
- Revenue Next Year
- ACET N/A
- HYPR $24.57
- P/E Ratio
- ACET N/A
- HYPR N/A
- Revenue Growth
- ACET N/A
- HYPR 0.34
- 52 Week Low
- ACET $0.45
- HYPR $0.53
- 52 Week High
- ACET $1.70
- HYPR $1.90
- Technical
- Relative Strength Index (RSI)
- ACET 56.33
- HYPR 65.29
- Support Level
- ACET $0.64
- HYPR $0.53
- Resistance Level
- ACET $0.72
- HYPR $0.67
- Average True Range (ATR)
- ACET 0.06
- HYPR 0.09
- MACD
- ACET 0.01
- HYPR 0.02
- Stochastic Oscillator
- ACET 74.37
- HYPR 48.25
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.